Screening new drugs for immunotoxic potential: III. Assessment of the effects of selective and nonselective COX-2 inhibitors on T-cell-dependent antibody and natural killer cell responses in the rat

Journal of Immunotoxicology

Volumn 2, Issue 3, 2005, Pages 161-170

  Furst, Sylvia M ^a   Khan, K Nasir ^a   Komocsar, Wendy J ^b   Mennear, John ^c  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CAMPBELL UNIVERSITY   (United States)

Author keywords

Anti asialo GM1 antibody; Cyclophosphamide; Immunotoxicity; Natural killer cell activity; Selective COX 2 inhibitors; T dependent antibody response; TDAR

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; ERYTHROCYTE ANTIBODY; GANGLIOTETRAOSYLCERAMIDE; NAPROXEN; SC 245; SC 791; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SCREENING; FEEDING; FEMALE; IMMUNIZATION; IMMUNOTOXICITY; LYMPHOCYTE DEPLETION; MALE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TOXICOKINETICS;

ANIMALIA; MURINAE; OVIS ARIES;

EID: 28244447363     PISSN: 16602854     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910500290567     Document Type: Article

References (28)

1. Ali, S. A., Lynam, J., McLean, C. S., Entwisle, C., Loudon, P., Rojas, J. M., McArdle, E. B., Li, G., Mian, S., and Rees, R. C. 2002. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) Herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J. Immunol. 168:3512-3519.
2. Aronoff, D. M., and Bloch, K. C. 2003. Assessing the relationship between the use of nonsteroidal anti-inflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine 82:225-235.
3. Browne, B. A., Holder, E. P., and Rupnick, L. A. 1996. Nonsteroidal anti-inflammatory drugs and necrotizing faciitis. Am. J. Health-Syst. Pharm. 53:265-269.
4. 1 cells. Eur. J. Immunol. 34:2579-2588.
5. Demeure, C. E., Yang, L. P., Desjardins, C., Raynauld, P., and Delespesses, G. 1997. Prostaglandin E primes naïve T-cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 27:3526-3532.
6. Furst, S. M., Komocsar, W. J., Khan, K. N., White, K. L., Peachee, V. L., and Mennear, J. H. 2004. Screening New Drugs For Immunotoxic Potential: I. Assessment of the effects of conventional and Selective COX-2 Inhibiting NSAIDs on in vitro and in vivo phagocytic activity. J. Immunotoxicol. 1:149-158.
7. Furst, S. M., Komocsar, W. J., Fan, L., Mennear, J. H., and Khan, K. N. 2005. Screening New Drugs for Immunotoxic Potential: II. Assessments of the effects of selective and nonselective COX-2 Inhibitors on complement activation, superoxide anion production and leukocyte chemotaxis and migration through endothelial cells. J. Immunotoxicol. 2:85-96.
8. Habu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K., and Tamaoki, N. 1981. In vivo effects of anti-asialo GM1. I Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127:34-38.
9. Holsapple, M. P. 1995. The plaque-forming cell (PFC) response in immunotoxicology: An approach to monitoring the primary effector function of B-lymphocytes. In Methods in Immunotoxicology (Burleson, G. R., Dean J. H., and Munson, A. E., Eds.), Vol. 1. Wiley-Liss: New York, pp. 71-108.
10. Iniguez, M. A., Martinez-Martinez, S., Punzon, C., Redondo, J. M., and Fresno, M. 2000. An essential role of the nuclear factor of activation T-cells in the regulation of the expression of the cyclooxygenase-2 gene in human T-lymphocytes. J. Biol. Chem. 275:23627-23635.
11. Iniguez, M. A., Punzon, C., and Fresno, M. 1999. Induction of cyclooxygenase-2 on activated T-lymphocytes: Regulation of T-cell activation by cyclooxygenase-2 inhibitors. J. Immunol. 163:111-119.
12. Kalinski, P., Hilkens, C. M., Snijders, A., Snijdewint, F. G., and Kapsenberg, M. L. 1997. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naïve T-helper cells. J. Immunol. 159:28-35.
13. Korytko, P. K., Senese, P. B., Sellers, R., Cai, W., Endo, Y., and Khan, K. N. M. 2003. Gastrointestinal and renal toxicity associated with loxoprofen sodium in dogs. Preclinica 1:107-113.
14. Levene, H. 1960. Robust test for equality of variances. In Contributions to Probability and Statistics (Olkin, I., et al., Eds.), Stanford University Press: Stanford, CA, pp. 278-292.
15. Luster, M. I., Munson, A. E., Thomas, R., Holsapple, M. P., Fenter, J., White Jr., K. L., Germolec, D. R., Resenthal, G. J., and Dean, J. H. 1988. Development of a testing battery to assess chemical-induced immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 10:2-19.
16. Maloney, C. G., Thompson, S.D., Hill, H. R., Bohnsack, J. F., McIntyre, J. F., and Zimmerman, G. A. 2000. Induction of cyclooxygenase-2 by human monocytes exposed to group B streptococci. J. Leukoc. Biol. 67:615-621.
17. Maziasz, T., Khan, K. N., Talley, J., Gierse, J., and Seibert, K. 2003. The development of drugs that target cyclooxygenase-2. In COX-2 Blockade in Cancel-Prevention and Therapy, Humana Press Inc., Totowa, NJ.
18. Miller, C. W., Prescott, J. F., Mathews, K. A., Betschel, S. D., Yager, J. A., Guru, V., DeWinter, L., and Low, D. E. 1996. Streptococcal toxic shock syndrome in dogs. JAVMA 209:1421-1426.
19. Newberry, R. D., Stenson, W. F., and Lorenz, R. G. 1999. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med. 5:900-906.
20. Ortize De Landazuri, M., and Herberman, R. B. 1972. In vitro activation of cellular immune response to gross virus-induced lymphoma. J. Exp. Med. 136:969-983.
21. Reynolds, C., Tompnen, T., and Herberman, R. B. 1981. Natural killer cell activity in the rat, isolation and characterization of the effector cells. J. Immunol. 127:282-287.
22. Ryan, E. P., Pollack, S. J., Murant, T. I., Bernstein, S. H., Felgar, R. E., and Phipps, R. P. 2005. Activated human B-lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174:2619-2626.
23. Stamp, L. K., James, M. J., and Cleland, L. G. 2004. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T-lymphocytes: Role of interleukin 17 and interferon-gamma. J. Rheumatol. 31(7):1255-1264.
24. Stevens, D. L. 1995. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin. Infect. Diseases 21:977-980.
25. Tanaka, K., Tanaka, H., Kanemoto, Y., and Tsuboi, I. 1998. The effects of non-steroidal anti-inflammatory drugs on immune functions of human peripheral blood mononuclear cells. Immunopharmacology 40:209-217.
26. Van der Pouw Kraan, T. C., Boeije, L. C., Smeenk, R. J., Wijdenes, J., and Aarden, L. A. 1995. Prostaglandin E2 is a potent inhibitor of human interleukin-12 production. J. Exp. Med. 181:775-779.
27. Verfaillie, G., Knape, S., and Corne, L. 2002. A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac. Eur. J. Emerg. Med. 9(3):270-273.
28. Wu, C. Y., Wang, K., McDyer, J. F., and Seder, R. A. 1998. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161:2723-2730.